• FDA Approves Decnupaz (pivekimab sunirine-pvzy) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

  May 27, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Decnupaz (pivekimab sun···【Read More】

  Update: 28 May,2026Source: Haiou HealthViews: 112

• Tazemetostat (TAZEDX) manufactured by Big Bear Pharmaceutical has been approved in Laos

  Vientiane, Laos, August 01, 2024 – BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer tre···【Read More】

  Update: 27 May,2026Source: Haiou HealthViews: 112

• FDA approves the first all-oral combination regimen for patients with acute myeloid leukemia who cannot tolerate intensive induction chemotherapy

  On May 13, 2026, Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved decit···【Read More】

  Update: 27 May,2026Source: Haiou HealthViews: 110

• BigBear Pharma announces that Olaparib (OLADX) has been approved in Laos

  September 20, 2024 - Vientiane, Laos - BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer···【Read More】

  Update: 26 May,2026Source: Haiou HealthViews: 118

• BigBearPharma announces that Letermovir (LETEDX) has been approved in Laos

  September 20, 2024 - Vientiane, Laos - BigBearPharma, a leading biopharmaceutical company focused on developing and commercializing innovative therapi···【Read More】

  Update: 26 May,2026Source: Haiou HealthViews: 265

• FDA Grants Accelerated Approval to Hepcludex (bulevirtide-gmod) Treatment for Chronic Hepatitis Delta Virus (HDV)

  FOSTER CITY, Calif.--(BUSINESS WIRE) May 22, 2026 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (···【Read More】

  Update: 25 May,2026Source: Haiou HealthViews: 127

• FDA Approves Inqovi for Acute Myeloid Leukemia

  FRIDAY, May 22, 2026 -- The U.S. Food and Drug Administration has approved Inqovi (decitabine and cedazuridine) plus venetoclax for the treatment of a···【Read More】

  Update: 25 May,2026Source: Haiou HealthViews: 128

• BigBear Pharma Announces Approval of Pralsetinib (PRASEDX) in Laos

  Vientiane, Laos, August 12, 2024 - BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer tre···【Read More】

  Update: 22 May,2026Source: Haiou HealthViews: 118

• Double "Zero" Breakthrough! Anti-cancer Drug from BigBear Pharma Laos Achieves First Export to ASEAN

  September 24, 2024 - Vientiane, Laos - Recently, BigBear Pharma Laos announced that it has received official permission from the Lao Ministry of Healt···【Read More】

  Update: 22 May,2026Source: Haiou HealthViews: 119

• Lusutrombopag manufactured by BigBear Pharmaceuticals approved in Laos

  Vientiane, Laos – October 08, 2024 – BigBear Pharma, a leading biopharmaceutical company focused on the development and commercialization of innovativ···【Read More】

  Update: 21 May,2026Source: Haiou HealthViews: 123

• FDA Approves Ocrevus (ocrelizumab) for Pediatric Patients 10 Years of Age and Older with Relapsing-Remitting Multiple Sclerosis

  Genentech, a member of the Roche Group, recently announced that the U.S. Food and Drug Administration (FDA) has approved Ocrevus (ocrelizumab) intrave···【Read More】

  Update: 21 May,2026Source: Haiou HealthViews: 112

• BigBear Pharmaceuticals of Laos Successfully Obtains GMP Certification for Its Traditional Medicine Processing Plant

  Laos, October 7, 2023 – BigBear Pharmaceuticals of Laos is pleased to announce that its Traditional Chinese Medicine processing facility has successfu···【Read More】

  Update: 20 May,2026Source: Haiou HealthViews: 122

• FDA Approves Baxfendy (baxdrostat) as the First Aldosterone Synthase Inhibitor Treatment for Adults with Hypertension

  May 18, 2026 – Baxfendy (baxdrostat) from AstraZeneca has received FDA approval as the world's first aldosterone synthase inhibitor (ASI) for use ···【Read More】

  Update: 20 May,2026Source: Haiou HealthViews: 127

• BigBear Pharma Announces Approval of Encorafenib (BRATODX) in Laos

  Vientiane, Laos – October 12, 2024 – BigBear Pharma, a leading biopharmaceutical company focused on the development and commercialization of innovativ···【Read More】

  Update: 19 May,2026Source: Haiou HealthViews: 109

• EU Recommends Expanding New Indications for Nivolumab (Opdivo)

  Recently, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending chan···【Read More】

  Update: 19 May,2026Source: Haiou HealthViews: 105